# Biomedical Research: Root Causes

## Overview

The challenges facing American biomedical research are not the result of any single failure but rather a system of interconnected structural incentives that produce suboptimal outcomes even when individual actors behave rationally within the rules. Six root causes drive the majority of dysfunction: hypercompetitive funding, the translational valley of death, perverse publication incentives, a reproducibility crisis, workforce structural problems, and pharmaceutical industry retreat from basic research.

## Root Cause 1: Hypercompetitive Funding Environment

### The Problem

NIH grant success rates have fallen to approximately 20%, meaning the vast majority of peer-reviewed and often meritorious proposals go unfunded. Researchers report spending 30-50% of their time writing grant applications rather than conducting science. This represents an enormous waste of scientific talent and creates a risk-averse culture that discourages bold, innovative research.

### How It Works

```text
More PhDs trained
        |
        v
More researchers competing for grants
        |
        v
More applications submitted
        |
        v
Budget growth does not keep pace
        |
        v
Lower success rates
        |
        v
Researchers submit more applications
        |
        v
Even more applications in the system
        |
        v
Success rates decline further (positive feedback loop)
```

### Structural Drivers

- **University expansion during the doubling**: Institutions hired faculty and built facilities during the 1998-2003 NIH doubling, creating fixed obligations that flat budgets could not sustain
- **Soft-money faculty positions**: Many medical school researchers must fund 50-80% of their own salaries from grants, creating existential pressure to secure funding
- **Short grant periods**: Standard R01 grants last 3-5 years, requiring constant renewal cycles
- **Application inflation**: When success rates drop, researchers submit more applications to maintain the same probability of funding, further lowering success rates
- **Reviewer fatigue**: Study sections face overwhelming application volumes, reducing review quality and increasing randomness in funding decisions

### Consequences

| Consequence | Impact |
|-------------|--------|
| Risk aversion | Researchers propose incremental, "safe" studies rather than innovative but uncertain ideas |
| Time waste | 30-50% of researcher time devoted to grantsmanship rather than research |
| Career instability | Even productive scientists face funding gaps that can end careers |
| Inequality | Established investigators with track records outcompete newcomers, regardless of idea quality |
| Mental health | Chronic stress, anxiety, and burnout among researchers |

## Root Cause 2: The Translational Valley of Death

### The Problem

An enormous gap exists between basic scientific discoveries and their translation into clinical applications. Fewer than 5% of basic research findings ultimately lead to approved therapies. Promising discoveries often languish in academic laboratories for years or decades because no mechanism exists to advance them through the expensive and complex process of preclinical development, toxicology testing, and early-phase clinical trials.

### Why the Gap Exists

- **Funding mismatch**: NIH funds basic research well, and pharmaceutical companies fund late-stage development well, but the middle stages are inadequately supported
- **Risk profile**: Translational work is too risky for industry (high failure rate, uncertain IP) and too applied for traditional NIH mechanisms
- **Academic incentives**: Faculty are rewarded for publications and grants, not for advancing discoveries toward clinical application
- **Expertise gap**: Academic researchers typically lack expertise in drug formulation, pharmacokinetics, manufacturing, and regulatory affairs
- **IP complications**: University technology transfer offices may set licensing terms that discourage industry partnerships

### The Valley in Practice

| Stage | Primary Funder | Estimated Cost | Key Challenges |
|-------|---------------|----------------|----------------|
| Basic discovery | NIH | $1-5 million | Identifying targets, validating mechanisms |
| Target validation | NIH / gap zone | $5-20 million | Reproducibility, assay development |
| Lead optimization | Valley of death | $20-50 million | Chemistry, pharmacology, toxicology |
| IND-enabling studies | Industry / gap zone | $10-30 million | Regulatory requirements, manufacturing |
| Phase I clinical trials | Industry | $15-30 million | Safety, dosing, recruitment |

The "valley of death" falls between target validation and IND-enabling studies, where neither NIH nor industry typically provides adequate support.

### Attempted Solutions and Their Limitations

- **NIH National Center for Advancing Translational Sciences (NCATS)**: Created in 2011 specifically to address this gap, but budget (~$900 million) is small relative to the problem
- **SBIR/STTR programs**: Small business grants provide some bridge funding, but amounts are limited and processes bureaucratic
- **University venture funds**: Growing but concentrated at elite institutions
- **ARPA-H**: Promising new model, but still establishing programs and track record

## Root Cause 3: Perverse Publication Incentives

### The Problem

The academic reward system revolves around publications, creating incentives that undermine research quality. The pressure to "publish or perish" encourages researchers to prioritize quantity over quality, overstate findings, suppress negative results, and slice research into the smallest publishable increments.

### How Incentives Distort Research

**Hiring and promotion:**

- Faculty candidates evaluated primarily on publication count and journal prestige
- Negative or null results are rarely published and do not advance careers
- Replication studies are viewed as uncreative and unrewarded

**Journal incentives:**

- High-impact journals (Nature, Science, Cell) favor novel, surprising, positive results
- Publication bias means the literature systematically overstates effect sizes
- Predatory journals proliferate, publishing low-quality work for fees
- Retraction rates have increased, suggesting quality control problems

**Citation dynamics:**

- H-index and impact factor metrics incentivize prolific publication and strategic citation
- Salami slicing (dividing one study into many papers) inflates publication counts
- Authors may overstate implications to attract citations

### The Distortion Cycle

```text
Publish or perish culture
        |
        v
Researchers seek novel, positive results
        |
        v
Negative/null results suppressed
        |
        v
Literature biased toward positive findings
        |
        v
Other researchers build on biased literature
        |
        v
Replication failures increase
        |
        v
Resources wasted on false leads
```

## Root Cause 4: The Reproducibility Crisis

### The Problem

A substantial fraction of published biomedical research findings cannot be reproduced by independent laboratories. Estimates of irreproducibility range from 50% to 90% depending on the field and methodology studied. This represents billions of dollars in wasted resources and delays in developing effective therapies.

### Key Evidence

| Study | Finding |
|-------|---------|
| Amgen (Begley & Ellis, 2012) | Could reproduce only 6 of 53 (11%) "landmark" cancer biology studies |
| Bayer (Prinz et al., 2011) | Could reproduce only ~25% of published preclinical findings |
| Reproducibility Project: Cancer Biology (2021) | Effect sizes in replications were 85% smaller on average than original claims |
| Open Science Collaboration (2015) | Only 36% of psychology studies replicated (applicable dynamics exist in biomedical fields) |

### Contributing Factors

- **Inadequate statistical methods**: Small sample sizes, p-hacking (analyzing data multiple ways to find significant results), lack of pre-registration
- **Insufficient methodological detail**: Published methods sections often lack information needed for replication
- **Biological complexity**: Cell line contamination, reagent variability, environmental conditions affect results
- **Selective reporting**: Only "successful" experiments are reported; failed experiments are hidden
- **Lack of replication incentive**: No career reward for confirming or disconfirming others' findings
- **Antibody and reagent quality**: Poorly characterized or variable research reagents contribute to irreproducible results

### Economic Impact

A 2015 study estimated that irreproducible preclinical research costs the United States approximately $28 billion annually in wasted resources, failed clinical trials, and delayed therapies (Freedman, Cockburn, and Simcoe, *PLOS Biology*).

## Root Cause 5: Workforce Pyramid Scheme

### The Problem

The biomedical research workforce operates on a structural model that resembles a pyramid scheme: it trains far more scientists than the system can employ in research positions, using trainees as a source of cheap, skilled labor to power established laboratories. This model harms individual scientists, distorts research priorities, and ultimately undermines the enterprise it claims to serve.

### The Numbers

```text
Training Pipeline (approximate):

  [~90,000 biomedical graduate students]
              |
              v
  [~60,000-70,000 postdoctoral researchers]
              |
              v
  [~5,000-7,000 new faculty positions/year]
              |
              v
  [~1,500-2,000 tenure-track offers/year]
```

Only about 15-20% of biomedical PhDs will secure tenure-track faculty positions. The median time from PhD completion to first tenure-track appointment has grown to 5-7 years of postdoctoral training.

### Why the System Persists

- **Cheap labor**: Graduate students and postdocs perform the majority of bench research at a fraction of the cost of hiring staff scientists
- **University incentives**: PhD programs generate tuition revenue, teaching labor, and (through external grants) indirect cost recovery
- **PI incentives**: Individual investigators benefit from having large teams of trainees
- **Cultural inertia**: The expectation that a PhD leads to a faculty position persists despite evidence to the contrary
- **Lack of alternatives information**: Trainees receive little exposure to non-academic career paths during their training

### Consequences for Science

| Problem | Effect on Research |
|---------|-------------------|
| Overproduction of PhDs | Intensifies funding competition, lowers success rates |
| Extended postdocs | Delays independent research, wastes years of peak productivity |
| Low trainee pay | Drives talented people to other fields; selects for privilege |
| Precarity | Risk aversion in research choices; mental health crises |
| Lack of diversity | Low pay and long timelines disproportionately exclude underrepresented groups |

## Root Cause 6: Pharmaceutical Industry Retreat from Basic Research

### The Problem

Over the past two decades, major pharmaceutical companies have dramatically reduced their investment in early-stage and basic research, instead focusing on later-stage development, acquisitions, and specialty drugs. This retreat has widened the translational gap and shifted more of the risk and cost of early discovery onto publicly funded institutions.

### The Shift

**What changed:**

- Large pharma companies closed or downsized internal research laboratories
- R&D investment shifted toward Phase III trials, regulatory affairs, and commercial development
- "Search and develop" replaced "research and develop" as companies acquired promising candidates from smaller firms and academic spinoffs
- Focus shifted toward diseases with large commercial markets (oncology, immunology) rather than greatest unmet need

**Why it happened:**

- **Declining R&D productivity**: Despite increased spending, the number of new drugs approved per billion dollars of R&D investment has fallen (Eroom's Law)
- **Patent cliff pressure**: Revenue declines when blockbuster drugs lose patent protection create pressure to cut costs
- **Shareholder pressure**: Quarterly earnings expectations discourage long-term, uncertain research investments
- **Financial engineering**: Stock buybacks and dividends compete with R&D for capital allocation
- **Regulatory burden**: Increasing regulatory requirements raise the cost and complexity of development

### Consequences

- Academic discoveries with therapeutic potential have fewer pathways to clinical development
- Small biotech companies, often funded by venture capital, have partially filled the gap but are constrained by short investment horizons and high-return expectations
- Diseases affecting small or poor populations (neglected tropical diseases, rare diseases, antibiotic-resistant infections) receive inadequate commercial investment
- The public bears more of the cost and risk of early-stage research while industry captures more of the profit from late-stage development

## Interconnections

These root causes are deeply interconnected and mutually reinforcing:

| Root Cause | Reinforces |
|------------|-----------|
| Hypercompetitive funding | Risk aversion, publication pressure, workforce stress |
| Valley of death | Industry retreat, wasted basic research investment |
| Publication incentives | Reproducibility crisis, quantity over quality |
| Reproducibility crisis | Translational failure, wasted funding, public trust |
| Workforce pyramid | Funding competition, diversity gaps, risk aversion |
| Industry retreat | Valley of death, orphaned discoveries, misaligned priorities |

Addressing any single root cause in isolation will have limited effect. Comprehensive reform requires simultaneous action across multiple dimensions of the biomedical research enterprise.

## References

- Alberts, Bruce, Marc W. Kirschner, Shirley Tilghman, and Harold Varmus. "Rescuing US Biomedical Research from Its Systemic Flaws." *Proceedings of the National Academy of Sciences* 111, no. 16 (2014): 5773-5777.
- Begley, C. Glenn, and Lee M. Ellis. "Raise Standards for Preclinical Cancer Research." *Nature* 483 (2012): 531-533.
- Freedman, Leonard P., Iain M. Cockburn, and Timothy S. Simcoe. "The Economics of Reproducibility in Preclinical Research." *PLOS Biology* 13, no. 6 (2015): e1002165.
- Lauer, Michael S., et al. "NIH Peer Review: Criterion Scores Completely Account for Racial Disparities in Overall Impact Scores." *Science Advances* 7, no. 47 (2021): eabj0675.
- Stephan, Paula. *How Economics Shapes Science*. Cambridge: Harvard University Press, 2012.

---

## Document Navigation

- Previous: [History](03-history.md)
- Next: [Stakeholders](05-stakeholders.md)
